Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Horizon Therapeutics (DE:HPR)
FRANKFURT:HPR
Horizon Therapeutics (HPR) Stock Price & Analysis
0 Followers
HPR Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€61.68 - €110.80
Previous Close€110.2
Volume0.00
Average Volume (3M)103.00
Market Cap
€25.20B
Enterprise Value€25.28B
Total Cash (Recent Filing)$2.47B
Total Debt (Recent Filing)$2.56B
Price to Earnings (P/E)N/A
Beta0.05
Next Earnings
Nov 08, 2023EPS Estimate
€1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding228,994,568
10 Day Avg. Volume0
30 Day Avg. Volume103
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)26.53
Price to Sales (P/S)26.70
Price to Cash Flow (P/CF)41.20
P/FCF Ratio46.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.94
Enterprise Value/Gross Profit9.33
Enterprise Value/Ebitda41.78
Forecast
1Y Price Target
€110.22Price Target Upside0.02% Upside
Rating ConsensusHold
Number of Analyst Covering2
Horizon Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.33% Other Institutional Investors
98.67% Public Companies and
Individual Investors
HPR FAQ
What was Horizon Therapeutics’s price range in the past 12 months?
Horizon Therapeutics lowest stock price was €61.68 and its highest was €110.80 in the past 12 months.
What is Horizon Therapeutics’s market cap?
Currently, no data Available
When is Horizon Therapeutics’s upcoming earnings report date?
Horizon Therapeutics’s upcoming earnings report date is Nov 08, 2023 which is 169 days ago.
How were Horizon Therapeutics’s earnings last quarter?
Horizon Therapeutics released its earnings results on Aug 08, 2023. The company reported €1.135 earnings per share for the quarter, beating the consensus estimate of €0.914 by €0.221.
Is Horizon Therapeutics overvalued?
According to Wall Street analysts Horizon Therapeutics’s price is currently Undervalued.
Does Horizon Therapeutics pay dividends?
Horizon Therapeutics does not currently pay dividends.
What is Horizon Therapeutics’s EPS estimate?
Horizon Therapeutics’s EPS estimate is €1.11.
How many shares outstanding does Horizon Therapeutics have?
Currently, no data Available
What happened to Horizon Therapeutics’s price movement after its last earnings report?
Horizon Therapeutics reported an EPS of €1.135 in its last earnings report, beating expectations of €0.914. Following the earnings report the stock price went up 4.983%.
Which hedge fund is a major shareholder of Horizon Therapeutics?
Among the largest hedge funds holding Horizon Therapeutics’s share is Soros Fund Mangment LLC. It holds Horizon Therapeutics’s shares valued at 339M.
---
Horizon Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€110.22 (0.02% Upside)
€110.22 (0.02% Upside)
Blogger Sentiment
Bullish
DE:HPR Sentiment 100%
Sector Average 68%
Sector Average 68%
Insider Transactions
Bought Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.12%
12-Months-Change
Fundamentals
Return on Equity
8.54%
Trailing 12-Months
Asset Growth
5.03%
Trailing 12-Months
Company Description
Horizon Therapeutics
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
---
HPR Stock 12 Months Forecast
Average Price Target
€110.22
▲(0.02% Upside)
Technical Analysis
Horizon Therapeutics
―
Ardelyx
―
Bausch Health Companies
―
Eagle Pharmaceuticals
―
Heron Therapeutics
―
Best Analysts Covering HPR
1 Year
1 Year Success Rate
20/28 ratings generated profit
1 Year Average Return
+42.89%
reiterated a buy rating a year ago
Copying Ken Cacciatore's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +42.89% per trade.
---